News

Advance Tests, committed to enhancing diagnostic accessibility and advancing early disease detection, announced the exclusive UK launch of LucentAD Complete.

LucentAD Complete, developed by Lucent Diagnostics, is a cutting-edge multi-marker blood test designed to deliver highly accurate risk assessment for amyloid pathology linked to Alzheimer’s disease. This advanced diagnostic tool integrates multiple Alzheimer’s-related biomarkers, including p-Tau 217, to improve early detection in individuals experiencing cognitive symptoms. Through an exclusive partnership between Lucent Diagnostics and Advance Tests, the test will be available to patients and healthcare providers across the UK starting 2 December, representing a major step forward in making Alzheimer’s diagnostics more accessible.

Dr Simon Worrell, founder and chief medical officer of Advance Tests comments, “We’re proud to exclusively bring LucentAD Complete to the UK, offering healthcare providers and patients a reliable and accessible diagnostic aid that can transform Alzheimer’s care. Our work with Quanterix strengthens our commitment to removing barriers to early diagnosis, enabling timely treatment that could profoundly impact patients’ lives.”

LucentAD Complete offers several key advantages, starting with its immediate availability, as appointments can be booked as early as 2 December. Patient samples will be securely transported to Lucent labs in the US, with results provided within 15 working days. This innovative test combines p-Tau 217 with additional biomarkers – Aβ42/40, GFAP and NfL – to enhance amyloid detection, providing conclusive results in around 90% of cases. Achieving 90% accuracy in early-stage Alzheimer’s detection, it meets the performance standards set by the Global CEO Initiative on Alzheimer’s Disease and the US Alzheimer’s Association for plasma-based diagnostics. Priced at £695, it offers a cost-effective alternative to costly PET scans and lumbar punctures. As a non-invasive blood test, it eliminates the need for cerebrospinal fluid collection or costly imaging, aligning with Advance Tests’ mission to provide accessible diagnostics. Furthermore, the inclusion of multiple biomarkers and a sophisticated algorithm reduces uncertainty, ensuring nearly 90% of patients receive a conclusive diagnosis, either confirming or ruling out Alzheimer’s disease, surpassing global standards.

“Having access to this sophisticated, non-invasive blood test is a game changer for early Alzheimer’s diagnosis in the UK,” stated Dr Karan Jutlla, head of the Centre for Applied and Inclusive Health Research, University of Wolverhampton, UK, on the introduction of LucentAD Complete. “By simplifying diagnostics, we’re helping more patients access critical care sooner, especially as new therapies for early-stage Alzheimer’s are becoming available.”

Lucent Diagnostics is a subsidiary of Quanterix, a a US-based company with a focus on digitising biomarker analysis to aid precision health.